Daniele Cattaneo
Overview
Explore the profile of Daniele Cattaneo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
130
Citations
1236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ballardini A, Cattaneo D, Sorrenti D, Parra Alonso I
Front Robot AI
. 2024 Nov;
11:1509637.
PMID: 39583945
No abstract available.
2.
Iurlo A, Bucelli C, Intermesoli T, Elena C, DAdda M, Agostani E, et al.
Acta Haematol
. 2024 Sep;
:1-5.
PMID: 39293408
Introduction: Up to 30% of CML patients will require a therapeutic change during follow-up due to intolerance and/or resistance to first-line tyrosine kinase inhibitor (TKI) approach. In this context, bosutinib...
3.
Cattaneo D, Bucelli C, Bellani V, Mora B, Iurlo A
Hematol Oncol
. 2024 Sep;
42(5):e3309.
PMID: 39275966
The therapeutic armamentarium of chronic myeloid leukemia (CML) has dramatically improved after small molecule tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 became available, with a life expectancy now close to that...
4.
Mora B, Bucelli C, Cattaneo D, Bellani V, Versino F, Barbullushi K, et al.
Curr Hematol Malig Rep
. 2024 Aug;
19(5):223-235.
PMID: 39179882
Purpose Of Review: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). Median overall survival (OS) of pre-PMF, overt-PMF and SMF patients is around 14 years, seven...
5.
Palandri F, Elli E, Morsia E, Benevolo G, Tiribelli M, Beggiato E, et al.
Cancer
. 2024 Jul;
130(24):4257-4266.
PMID: 39078647
Background: Ruxolitinib (RUX) is a JAK1/2 inhibitor approved for the therapy of myelofibrosis (MF) based on clinical trials including only intermediate2-high risk (INT2/HIGH) patients. However, RUX is commonly used in...
6.
Cattaneo D, Marchetti A, Bucelli C, Galli N, Lionetti M, Bellani V, et al.
Clin Exp Med
. 2024 Jul;
24(1):165.
PMID: 39042228
Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 28 consecutive patients admitted to our hospital between September 2011 and November 2021 for...
7.
Capitanio D, Calledda F, Abbonante V, Cattaneo D, Moriggi M, Niccolo B, et al.
Leukemia
. 2024 Jul;
38(9):1971-1984.
PMID: 39025985
Despite increased understanding of the genomic landscape of Myeloproliferative Neoplasms (MPNs), the pathological mechanisms underlying abnormal megakaryocyte (Mk)-stromal crosstalk and fibrotic progression in MPNs remain unclear. We conducted mass spectrometry-based...
8.
Rocca B, Tosetto A, Petrucci G, Rossi E, Betti S, Soldati D, et al.
Am J Hematol
. 2024 Jun;
99(8):1462-1474.
PMID: 38877813
Patients with essential thrombocythemia (ET) are treated with once-daily low-dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short-term Aspirin Regimens in EsSential Thrombocythemia...
9.
Cattaneo D, Galli N, Bucelli C, Fidanza C, Bellani V, Artuso S, et al.
Ann Hematol
. 2024 Jun;
103(8):2787-2795.
PMID: 38864904
We evaluated RDW in a single-center series of 61 consecutive patients with primary and secondary MF at diagnosis and during treatment with ruxolitinib (RUX) and examined any possible prognostic impact....
10.
Maronese C, Derlino F, Moltrasio C, Cattaneo D, Iurlo A, Marzano A
Front Med (Lausanne)
. 2024 Jan;
10:1324258.
PMID: 38249974
Cutaneous manifestations of hematologic malignancy represent both a clinical challenge for the treating physician and a pathophysiological model for advancing the knowledge on individual neoplasms. Indeed, a growing body of...